AUTHORS
Modesty Obasohan, MD, Arielle Lavi2, Nirajan Puri, MPH3, Elyse Mandell, NP4, Maureen Okam Achebe Jr, MD, MPH5
AFFILIATIONS
1 Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
2 Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
3 Brigham & Women's Hospital, Boston, Massachusetts, United States
4 Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
5 Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Introduction:
Correction of anemia has the benefit of improving oxygenation of tissues, lowering the need for red cell transfusion, and improving quality of life by improving cognition and fatigue (Crawford et al. 2002). Anemia in cancer patients, regardless of the tumor type, is more prevalent than in the general population, and affects 30-90% of patients (Knight et al. 2004). Cancer-associated anemia is associated with reduced quality of life, poor treatment tolerance, and worse overall survival. The etiology of cancer-associated anemia is multi-factorial and over 50% are complicated by iron deficiency (Luporsi et al. 2024). Clinical practice guidelines by ESMO (Aapro et al. 2018) and ASH/ASCO (Bohlius et al. 2019) recommend evaluating and treating iron deficiency (ID) early in cancer patients with anemia, but whether this has translated to clinical practice is unclear. With ID being a reversible contributor to anemia in cancer patients, the purpose of this study is to assess the frequency of evaluation for ID in a cohort of patients with cancer-associated anemia, assess the frequency of treatment with parenteral or oral iron, and assess if anemia outcomes in the treated cohort are improved compared to patients not treated with iron.
Methods:
This is a retrospective cohort study of adult patients actively undergoing cancer treatment at a major cancer institute between 1/1/2022 and 7/1/2025. Data was extracted via query of the Mass General Brigham Research Patient Data Registry (RPDR) on patients treated at Dana Farber Cancer Institute (DFCI) for a solid tumor or hematologic malignancy, excluding non-melanoma skin cancer, who received active anti-cancer treatment during the study period. Anemia was defined as hemoglobin (Hgb) ≤12.9 g/dL for men and ≤11.9 g/dL for women, and ID was defined as ferritin <100 ng/mL and transferrin saturation (TSAT) <20%. To evaluate the efficacy of iron treatment, anemic patients with ID were stratified by sex at birth and iron treatment status and assessed for the primary outcome, which was positive response at 6 to 12 weeks defined as TSAT increase to ≥20%, Hgb increase of ≥1g/dL, or correction of prior anemia. Results were summarized with descriptive statistics. Relative risks were adjusted with modified Poisson regression with empirical standard errors. Follow up Hgb was compared using a baseline adjusted linear model. All analyses were conducted using SAS 9.4. Ethics approval was granted by DFCI Institutional Review Board.
Results:
During the study period, 9,894 patients met criteria for anemia. In the 28 days following the first low hemoglobin value, only 11.4% (n=1,121) of patients received either ferritin or TSAT laboratory assessment. The overwhelming majority, 88.6% were not evaluated for ID. Of the patients evaluated for ID, 931 patients (83.1%) met criteria for iron deficiency and 573 (61.5%) received treatment. Most treated patients received parenteral iron. 624 patients (400 treated and 224 untreated) had sufficient data for assessment of the primary outcome. After adjustment for sex at birth, age, baseline HGB, ferritin, calculated TSAT, and time from iron deficiency identification to the index date, iron treatment was associated with a higher probability of positive response (65.3% vs. 38.1%; adjusted RR, 1.45; 95% CI, 1.20–1.75; p=0.0001). Mean Hgb change was +1.39 g/dL in the treated group vs. +0.36 g/dL in the untreated group (adjusted difference, +0.54 g/dL; 95% CI, 0.35–0.74; p<0.0001). The adjusted association between treatment and response was statically significant among female patients but not among male patients (adjusted RR, 1.77 vs. 1.15; 95% CI, 1.35–2.33 vs. 0.90–1.47; p<0.0001 vs. p=0.2534). Treatment with iron was associated with higher rates of Hgb increase ≥1g/dL (58.5% vs. 26.9%; p<0.0001), but TSAT increase to ≥20% was similar in both groups (51.2% vs. 50.0%).
Conclusion:
Only 11% of patients with cancer-associated anemia in this cohort received prompt investigation for ID, and the large majority of those investigated met criteria for ID. Iron treatment was associated with improved quantitative anemia outcomes. These findings support the need for universal evaluation for ID in anemic cancer patients as it presents a substantial opportunity to improve patients' cancer-associated anemia, linked to improved clinical outcomes and quality of life. Further analysis will assess the effect of ID treatment on other cancer-related outcomes.
DISCLOSURES
Modesty Obasohan, MD: No relevant conflicts of interest to declare.